Skip to main content
Peptide materials for immunomodulation

Peptide materials for immunomodulation

Value Proposition Glatiramoids are biomaterials synthesized for use as immunomodulators. Specifically, they are polypeptide mixtures with randomized amino acid sequences. Glatiramoids are currently FDA approved for use in multiple sclerosis. They have also been explored…

Read More

Strengthening a patient’s immune functions to prevent infectious diseases without developing antibiotic resistance

Strengthening a patient’s immune functions to prevent infectious diseases without developing antibiotic resistance

Unmet Need Despite the development of numerous antibiotics over the years, the arms race between humans and emergent antibiotic-resistant microbes remains. More than 2.8 million antibiotic-resistant infections and 35,000 deaths occur in the U.S. each…

Read More

Novel small molecule mast cell activator vaccine adjuvants

Novel small molecule mast cell activator vaccine adjuvants

Value Proposition Mast cells (MCs) are innate immune cells highly prevalent in the dermal region of the skin and in the respiratory, gastrointestinal, and urinary tract mucosa. The strategic location at the host–environment interface and…

Read More

Sublingual immunization using supramolecular peptide-polymer conjugate tablets

Sublingual immunization using supramolecular peptide-polymer conjugate tablets

Value proposition Immunization with vaccines prevent illness, disability, and currently avert an estimated 2 to 3 million deaths every year. However, commonly-used vaccine technology platforms can be unpredictable, require a high manufacturing cost, and often…

Read More

Beta-arrestin inhibition to prevent S1P1 internalization as a treatment for intracranial diseases

Beta-arrestin inhibition to prevent S1P1 internalization as a treatment for intracranial diseases

Value Proposition Glioblastomas (GBMs) are among the most common and deadly malignant brain tumors with a mean survival time of approximately 14-15 months following diagnosis. Current treatments for GBMs include surgery, radiation, and chemotherapy, however,…

Read More

Methods for treating pain and predicting cancer immune therapy efficacy

Methods for treating pain and predicting cancer immune therapy efficacy

Value proposition Chronic pain is a major health problem that affects approximately 1.5 billion people worldwide. The annual economic cost of chronic pain in the United States, including both treatment and lost productivity is estimated…

Read More

A therapeutic formulation for preventing posttraumatic osteoarthritis after joint injuries

A therapeutic formulation for preventing posttraumatic osteoarthritis after joint injuries

Value Proposition Osteoarthritis (OA) is an affliction of the joints that affects approximately 27 million people in the U.S . Posttraumatic osteoarthritis (PTOA), or osteoarthritis occuring after joint injury, accounts for approximately 12% of these…

Read More

Components of the Wnt-Beta-catenin paracrine signaling pathway as predictive biomarkers for cancer immunotherapy

Components of the Wnt-Beta-catenin paracrine signaling pathway as predictive biomarkers for cancer immunotherapy

Value Proposition Immunotherapy is a promising approach for the treatment of many cancers. However, despite early success, majority of patients with advanced cancer fail to respond or become resistant. In even the most immunogenic cancer…

Read More

Inhibition of endosomal TLR-activation with nucleic acid binding polymers

Inhibition of endosomal TLR-activation with nucleic acid binding polymers

Value Proposition Inflammatory and autoimmune diseases are the result of improper activation of the immune system, and can have chronic debilitating effects on quality of life. This inflammation is mediated by pattern recognition receptors (PRRs)…

Read More

Induction of immunogenic cell death in cancer cells using modified ssRNAs

Induction of immunogenic cell death in cancer cells using modified ssRNAs

Value proposition Cancer immunotherapy is showing great promise against numerous cancer types in clinical trials. Consequently, this market is projected to rapidly grow to over $200 billion by 2021. Among the list of effective immunotherapies…

Read More

Enhancing of homing and/or engraftment of cord blood mononuclear cells in the central nervous system

Enhancing of homing and/or engraftment of cord blood mononuclear cells in the central nervous system

Value Proposition Leukodystrophies are inherited disorders resulting in decreased motor function, muscle rigidity, degeneration of sight and hearing, and are ultimately fatal. There is a great lack of treatment, although cord blood mononuclear (CBM) and…

Read More

Ex vivo scavenging of pro-inflammatory nucleic acids by electrospun cationic nanofibers

Ex vivo scavenging of pro-inflammatory nucleic acids by electrospun cationic nanofibers

Value proposition Chronic wounds are a challenge to treat and consume a great deal of healthcare resources around the globe. In the setting of chronic wounds, dead and dying cells are continuously releasing nucleic acids…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us